https://techpapersworld.com/wp-content/uploads/2022/06/OSE-Immunotherapeutics-Announces-1280x720.jpg

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups. This program was launched during the 6th edition of “Viva Technology”, the most important Startup and Tech event organized in Europe being held in Paris from June 15-18, 2022. Microsoft France’s « Biotech Scaler Program » aims to support companies...